NovavaxInc has enroled 30,000 people in a late-stage trial of its COVID-19 vaccine in the United States and Mexico.

The company had stated last month that its vaccine had an efficacy of 89.3% to prevent COVID-19 in a trial done in the United Kingdom, and was almost as effective against the more contagious variant first detected in the UK. It has now enroled people aged 18 and above across the United States and Mexico in the trial. The company has deals to produce the two-dose vaccine, currently being reviewed on real-time basis in the European Union, at several manufacturing units, including the Serum Institute of India. Previously, the company had stated that the trial participants in the U.S. will be observed for about six weeks before results are reviewed… (Reuters, February 22, 2021)